Tag: Prolacta Bioscience

Enrollment Completed in Clinical Trial Evaluating Effect of Exclusive Human Milk Diet Including a Specialty Fortifier in Term Infants Born With Single Ventricle Physiology

DUARTE, Calif., April 7, 2021 /PRNewswire/ — Prolacta Bioscience, the world’s leading hospital provider of 100% human milk-based nutritional products, announced today that enrollment is now complete in a clinical trial evaluating the effect of an exclusive human milk diet (EHMD),1 including a specialty fortifier, for term infants who have undergone a corrective procedure for […]